Iktos
France
- Paris
- 10/03/2023
- Series A
- $16,428,000
We are Iktos. A start-up company specializing in the development of proprietary artificial intelligence technologies and software for ligand-based and structure-based de novo drug design focusing on multi parametric optimization.
Our de novo design algorithm is based on deep generative models with reinforcement learning. It designs novel and easy to make compounds, optimized to meet a given multi-objective blueprint, with unprecedented speed, performance, and diversity.
Please visit our webpage to know more about our products and offerings
https://iktos.ai/products/
- Industry Biotechnology
- Website https://iktos.ai/
- LinkedIn https://www.linkedin.com/company/iktos/
Related People
Yann Gaston-MatheFounder
France -
Greater Paris Metropolitan Region
I am a senior Life Science professional with extensive experience in Pharma R&D and Data Analytics for Life Science and Healthcare. I am an entrepreneur at heart, I have started several biotech companies, and I am the co-founder and CEO of Iktos, a start-up company specialising in artificial intelligence technology for chemical optimization in drug discovery.
WealthAi | $1,000,000 | (Jan 30, 2026)
Checkbox | $23,000,000 | (Jan 30, 2026)
PaleBlueDot AI | $150,000,000 | (Jan 30, 2026)
Mesh Security | $12,000,000 | (Jan 30, 2026)
Datalinx AI | $4,200,000 | (Jan 30, 2026)
Ressio Software | Undisclosed Amount | (Jan 30, 2026)
Co-reactive | $7,754,157 | (Jan 30, 2026)
Arkero | $6,000,000 | (Jan 30, 2026)
Redwood Materials | $425,000,000 | (Jan 30, 2026)
Twogee Biotech | $2,575,886 | (Jan 30, 2026)
Levellr | $2,500,000 | (Jan 30, 2026)
Indigo(1) | $50,000,000 | (Jan 30, 2026)
heyData | $16,500,000 | (Jan 30, 2026)